This inventor holds 1 USPTO granted patent, plus 6 CIPO patents. Top assignee: Daewoong Pharmaceutical Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Min Jae Cho: Innovator in Pharmaceutical Compounds
Introduction
Min Jae Cho is a notable inventor based in South Korea, recognized for his contributions to the field of pharmaceutical compounds. His work primarily focuses on developing innovative solutions for pain management and diseases caused by abnormal enzyme activity.
Latest Patents
Min Jae Cho has recently developed several significant patents. One of his latest inventions is related to Sodium Channel Blockers, which are compounds that exhibit a blocking effect against sodium ion channels, particularly Nav1.7. This invention aims to provide effective prevention or treatment for various types of pain, including acute pain, chronic pain, and neuropathic pain. Another notable patent involves a benzimidazole compound designed to prevent or treat diseases caused by abnormal prolyl-tRNA synthetase (PRS) activity. This compound has a novel structure and is accompanied by a method for its preparation and a pharmaceutical composition.
Career Highlights
Throughout his career, Min Jae Cho has focused on addressing critical health issues through innovative pharmaceutical research. His work has the potential to significantly impact the treatment of pain and related disorders, showcasing his commitment to advancing medical science.
Collaborations
Min Jae Cho has collaborated with notable colleagues, including Ji Duck Kim and Hong-Chul Yoon, to enhance the development of his inventions. These collaborations have contributed to the refinement and effectiveness of his patented compounds.
Conclusion
Min Jae Cho stands out as an inventor dedicated to creating innovative pharmaceutical solutions. His work in developing sodium channel blockers and compounds for treating diseases caused by abnormal PRS activity highlights his significant contributions to the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile